Health Care

Curis Inc. raises $80.8 M in a private placement to fund emavusertib, yet its single‑drug pipeline, volatile stock, and steep competition raise major risks for investors.

Penumbra Inc. shows high‑valuation growth and market volatility, with a focus on neurovascular devices; investors await fresh data to gauge future stability.

CG Oncology’s $3.38 billion market cap and Nasdaq-listed stock is poised to advance a promising bladder‑sparing cancer therapy, highlighted at the 2026 J.P. Morgan Healthcare Conference.

Humacyte’s new data on preventable extremity arterial costs highlights how bioengineered tissues could slash surgical expenses, while the company’s stock struggles show market uncertainty and the promise of future growth.

Lexicon Pharmaceuticals (LXCN) at the 44th J.P. Morgan Healthcare Conference—overview of its biopharma focus, 2026 market data, and valuation insights.

Discover why Sienna Senior Living Inc. remains a top Ontario senior‑living investment, with steady stock performance, strong market cap and growth‑focused strategy.

Hengrui’s Ruilafupa‑α injection gains NMPA approval, boosting its oncology portfolio, investor confidence, and positioning the company for rapid growth and global expansion.

Immunocore’s 2026 roadmap shows how a UK‑based biotech can shift from niche to industry‑leading, expanding KIMMTRAK, PRAME and HIV trials to unlock massive upside—UBS says it’s a “Buy” with 67% upside potential.

Satellos Bioscience: Toronto‑listed biotech pushing skeletal muscle regeneration, Phase 1 SAT‑3247 data at World Muscle Society, promising stock outlook.

Discover how Cresco Labs’ new Sunnyside Tamarac dispensary expands Florida’s cannabis market and boosts its vertical‑integration strategy.